Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to human transforming growth factor beta (TGF-β). This innovative approach targets solid tumors by simultaneously engaging two key pathways involved in cancer growth and immune suppression. The company's pipeline is centered on this bifunctional platform, aiming to improve outcomes for patients with difficult-to-treat cancers. As a clinical-stage company, Bicara is primarily engaged in research and development activities to advance its therapeutic candidates through clinical trials.

Bicara Therapeutics Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol BCAX. Its shares are traded in United States Dollars (USD), which is the standard currency for stocks listed on U.S. exchanges. The NasdaqGM is a tier of the Nasdaq stock exchange that lists companies meeting specific financial and liquidity requirements, providing investors with access to a regulated and transparent trading environment. Being listed on a major U.S. exchange like NasdaqGM offers Bicara visibility among institutional and retail investors globally.

Bicara Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes, organisms, or cellular systems to develop products and therapies, often focusing on areas like oncology, immunology, and genetic disorders. As a biotechnology firm, Bicara is involved in cutting-edge research and development of novel treatments, particularly bifunctional antibodies for solid tumors. This industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant potential for breakthrough therapies. The Healthcare sector encompasses a wide range of companies, including pharmaceuticals, medical devices, and healthcare services, with biotechnology being a key subsector driving innovation in medicine.

Bicara Therapeutics Inc. is headquartered in Boston, Massachusetts, United States. The company was incorporated in 2018, making it a relatively young player in the biotechnology space. Boston is a major hub for biotechnology and life sciences, home to numerous research institutions, hospitals, and biotech firms, providing a rich ecosystem for innovation and collaboration. Bicara's focus on developing bifunctional therapies for solid tumors reflects the cutting-edge research often found in this region. The company's incorporation date indicates it has been operating for about six years as of 2024, a typical timeframe for a clinical-stage biotech to advance its lead candidate through early-stage clinical trials.